Monoklonal gammopati med ubestemt signifikans

Niels Emil Ulrich Hermansen; Trine Silkjaer; Charlotte Toftmann Hansen; Thomas Granum Aagaard; Henrik Gregersen

Monoklonal gammopati med ubestemt signifikans

Niels Emil Ulrich Hermansen, Trine Silkjaer, Charlotte Toftmann Hansen, Thomas Granum Aagaard, Henrik Gregersen

KI, Hæmatologi

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström’s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

Bidragets oversatte titel	Monoclonal gammopathy of undetermined significance
Originalsprog	Dansk
Artikelnummer	V08190428
Tidsskrift	Ugeskrift for Laeger
Vol/bind	182
Udgave nummer	20
ISSN	0041-5782
Status	Udgivet - 2. mar. 2020

Dokumenter og links

https://ugeskriftet.dk/videnskab/monoklonal-gammopati-med-ubestemt-signifikans

Fingeraftryk Dyk ned i forskningsemnerne om 'Monoklonal gammopati med ubestemt signifikans'. Sammen danner de et unikt fingeraftryk.

Citationsformater

@article{2bb7723ad86f4e54a25254dd687858e5,

title = "Monoklonal gammopati med ubestemt signifikans",

abstract = "This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenstr{\"o}m{\textquoteright}s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.",

author = "Hermansen, {Niels Emil Ulrich} and Trine Silkjaer and {Toftmann Hansen}, Charlotte and Aagaard, {Thomas Granum} and Henrik Gregersen",

year = "2020",

month = mar,

day = "2",

language = "Dansk",

volume = "182",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

TY - JOUR

T1 - Monoklonal gammopati med ubestemt signifikans

AU - Hermansen, Niels Emil Ulrich

AU - Silkjaer, Trine

AU - Toftmann Hansen, Charlotte

AU - Aagaard, Thomas Granum

AU - Gregersen, Henrik

PY - 2020/3/2

Y1 - 2020/3/2

N2 - This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström’s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

AB - This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström’s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

M3 - Tidsskriftartikel

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 20

M1 - V08190428

ER -